枯草杆菌联合标准三联疗法治疗幽门螺杆菌感染临床疗效

摘要

Objective:To evaluate the clinical efficacy and value of adjuvant treatment of Helicobacter pylori (Hp) infection with bacillus subtilis.Methods:267 patients from outpatient or ward of department of gastroenterology in our hospital were enrolled in this experiment from April 2014 to March 2017.All the patients were confirmed to have functional dyspepsia and Hp infection.We excluded the patients who had taken the drugs that may influence this study observation or had a history of Hp infection but took failed eradication therapy.All patients were divided into two groups randomly,the control group and the study group.The patients in the control group took the following drugs for 2 weeks,the amoxicillin and clavulanate potassium tablets,the clarithromycin tablet and the pantoprazole enteric-coated tablets.The patients in the study group took the following drugs for 2 weeks,the live combined bacillus subtilis and enterococcus faecium enteric-coated capsules,the amoxicillin and clavulanate potassium tablets,the clarithromycin tablet and the pantoprazole enteric-coated tablets.After 2 weeks,all the patients stopped taking all the drugs.6 weeks later,all the patients were evaluated whether Hp had been eradicated successfully by 13C-UBT.We recorded the adverse reactions at the 1st week and the 2nd week.Hp eradication rate and the adverse reaction rate were compared between the two groups.Results:The total eradication rate of the study group which was added live combined bacillus subtilis and enterococcus faecium enteric-coated capsules was 89.6％,which was significantly higher than the control group (76.5％,P ＜ 0.05).The adverse reaction rate in the study group(6.7％)was significantly lower than that of the control group(18.9％,P ＜0.05).Conclusion:The live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined triple therapy can improve the eradication rate of Hp,reduce the incidence of adverse reactions,and improve the eradication effect of Hp.%目的:对枯草杆菌辅助治疗幽门螺杆菌(Helicobacter pylori,Hp)感染的临床疗效与价值进行评估.方法:选取2014年4月至2017年3月在我院消化内科门诊及病房就诊的267例符合纳入标准的Hp阳性患者,全部入组患者均被确诊功能性消化不良,除外试验2周内曾服用影响本试验观察的药物或既往有过Hp感染且根除治疗失败的患者.将所有入组患者随机分为研究组和对照组.对照组患者予以阿莫西林克拉维酸钾片、克拉霉素片和泮托拉唑肠溶片;研究组患者予以阿莫西林克拉维酸钾片、克拉霉素片、泮托拉唑肠溶片和枯草杆菌屎肠球菌二联活菌肠溶胶囊.2周后停止服用所有药物,第6周复查13C尿素呼气试验.试验第1周、第2周时记录患者不良反应发生情况.比较两组的Hp根除率及不良反应发生率.结果:总根除率方面,加入了枯草杆菌屎肠球菌二联活菌肠溶胶囊的研究组为89.6％,显著高于对照组的76.5％,差异有统计学意义(P＜0.05);不良反应方面,研究组(6.7％)显著低于对照组(18.9％),差异有统计学意义(P＜0.05).结论:应用枯草杆菌屎肠球菌二联活菌肠溶胶囊联合标准三联疗法治疗Hp感染有利于提高Hp根除率,减少不良反应的发生,改善治疗效果.